CDER’s Galson Cites Application Flaws, Not Politics, In Plan B Decision
This article was originally published in The Tan Sheet
Executive Summary
Barr Labs submitted a marketing plan for behind-the-counter sale of Plan B (levonorgestrel .75 mg), but FDA was "unable" to review the package
You may also be interested in...
Like Plan B, Approval For OTC Daily Oral Contraceptives In US Could Be An 'Adventure’
It was only after prolonged litigation led a federal judge in 2013 to order FDA not to allow political interference with its science-based decisions that Plan B and generic equivalents became available OTC without age restrictions. “Hopefully, all I can say, it won't happen again,” says reproductive rights advocate Kirsten Moore.
Barr Submits Plan B Response To FDA, Starts 180-Day Review Clock
An FDA decision on OTC availability of Barr Labs' Plan B emergency contraceptive is expected by the end of January
House Democrats Take Plan B Battle To Appropriations Bill
An amendment intended to support the over-the-counter switch of emergency contraceptive Plan B (levonorgestrel) survived debate on the House floor July 13